Strong Buy
Average AnalystStrong Buy
Top AnalystBearish
Stock Target AdvisorStrong Buy
Average UserUSD 12.74
0.00 (0.00%)
USD 1.84B
0.98M
USD 34.99(+174.61%)
Based on the Denali Therapeutics Inc stock forecast from 11 analysts, the average analyst target price for Denali Therapeutics Inc is USD 34.99 over the next 12 months. Denali Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Denali Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Denali Therapeutics Inc’s stock price was USD 12.74. Denali Therapeutics Inc’s stock price has changed by +0.31% over the past week, -12.80% over the past month and -20.38% over the last year.
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.